1
Clinical Trials associated with HLA-A*2402 Restricted Epitope Peptides Drived From URLC10 Vaccine(Kinki University)Tumor Vaccine Therapy Against Advanced Esophageal Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10
The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent esophageal cancer.
100 Clinical Results associated with HLA-A*2402 Restricted Epitope Peptides Drived From URLC10 Vaccine(Kinki University)
100 Translational Medicine associated with HLA-A*2402 Restricted Epitope Peptides Drived From URLC10 Vaccine(Kinki University)
100 Patents (Medical) associated with HLA-A*2402 Restricted Epitope Peptides Drived From URLC10 Vaccine(Kinki University)
100 Deals associated with HLA-A*2402 Restricted Epitope Peptides Drived From URLC10 Vaccine(Kinki University)